Immunome Inc

NASDAQ:IMNM   1:59:26 PM EDT
9.25
-0.02 (-0.22%)
Products, Regulatory

Immunome Announces Submission Of An IND Application For IMM-BCP-01 For The Treatment Of COVID-19

Published: 11/29/2021 12:35 GMT
Immunome Inc (IMNM) - Immunome Announces Submission of an Investigational New Drug (ind) Application for Imm-bcp-01 for the Treatment of Covid-19.
Immunome - Imm-bcp-01 Targets 3 Non-overlapping Regions on Spike Protein to Provide Broad Coverage Across Cdc Current and Former Variants of Concern.
Immunome - Imm-bcp-01 Elicits Multi-modal Activity in Pre-clinical Testing Including Ace2 & Non-ace2 Dependent Neutralization.
Immunome - to Initiate Placebo-controlled Dose Escalation Study of Imm-bcp-01 in Patients Infected With Sars-cov-2, Pending FDA's Acceptance of Ind.